Supportive of this notion, direct targeting of ADAR in tumor cells is sufficient to induce anti-tumor immunity, lead to tumor cell lethality, and can enhance the anti-tumor response to immune checkpoint blockade [4,21]. This evidence concerns the gene ADAR and neoplasm.